Pfizer Pharmaceutical Company: The World's Largest Pharmaceutical Company

Diflucan Partnership

Goal: To provide treatment for AIDS-related fungal infections in developing countries where HIV/AIDS is endemic

Targeted Area: Developing countries with priority given to those countries with greater than 1 percent HIV/AIDS prevalence

Start Date: 2000

Pfizer's Commitment: To provide Diflucan® (fluconazole), an antifungal to treat two fungal opportunistic infections associated with AIDS, free of charge to governmental and nongovernmental organizations in developing countries with a greater that 1% prevalence of HIV/AIDS.

Partners: Axios International, International Dispensary Association (IDA), IMA World Health, governments and NGOs

Successes:

  • More than $840 million in medicine donated to more than 2000 sites in 60 countries in Africa, Asia, the Caribbean and Latin America
  • More than 20,000 health professionals trained in the diagnosis and treatment of fungal opportunistic infections
pdf

If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.
Looking for a Pfizer Product?
A B-D E-H
I-N O-P R-Z
A-B C D-E
F-L M-P R-U V-Z
Additional Resources

Learn more about the Diflucan Partnership Program.

The International Trachoma Initiative

Learn more about this important global access program.

Learn more about other industry access programs.